Aldagen, Inc. IND For Stem Cell Clinical Trial To Treat Critical Limb Ischemia Is Cleared By FDA

DURHAM, N.C.--(BUSINESS WIRE)--April 13, 2006--Aldagen, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to conduct a clinical trial using Aldagen’s ALDESORT product to isolate a unique stem cell population for therapy for critical limb ischemia patients. It will be the first clinical trial involving this unique cell population for therapy for critical limb ischemia patients in the United States.